Protagonist Therapeutics

Youtube Subscribe

Open: 26.0 Close: 26.01 Change: 0.01

11 risks of investing in Protagonist Therapeutics Stock found by an AI after reading the whole internet.

This document will help you to evaluate Protagonist Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Protagonist Therapeutics are: Protagonist, Therapeutics, deal, Takeda, Inc, rare, drug, …

Concept Map

Semantic Network

Stock Summary

Protagonist Therapeutics, Inc. develops peptide-based drugs for hematology and blood disorders. Rusfertide (PTG-300) is in Phase II clinical trials for the treatment of erythrocyt.

Today's Summary

Protagonist Therapeutics shares rise 5.6% on licensing deal with takeda. Japanese pharmas financial numbers showed a drop in operating revenue. Takeda Pharmaceutical is stocking up its rare disease drug pipeline.

Today's News

Protagonist Therapeutics shares rise 5.6% on licensing deal with takeda - marketwatch.com. protagonist therapeutics inks deal with Takeda on rusfertide - tipranks.com. Takeda and Protagonist Therapeutics, Inc. signed a $300 million license and collaboration agreement with Protagonist. The Japanese pharmas financial numbers showed a drop in operating revenue. Takeda Pharmaceutical is stocking up its rare disease drug pipeline, reaching a deal for global rights to a Protagonist Therapeutics drug in late-stage development for the treatment of the rare blood disorder polycythemia vera. Protagonist Therapeutics, Inc. (PTGX) NASDAQ: PTGX · IEX Real-Time Price · USD Add to Watchlist 26.01 -0.48 (-1.81%) At close: Feb 5, 2024, 4:00 PM 25.51 -0.50 (-1.92%) After-hours: Feb 4, 2024 - 1.92% Share your thoughts via the Investor Exchange Matche robotic Inspectionira naturally 265 divisionAsh

Stock Profile

"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California."

Keywords

How much time have you spent trying to decide whether investing in Protagonist Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Protagonist Therapeutics are: Protagonist, Therapeutics, deal, Takeda, Inc, rare, drug, and the most common words in the summary are: protagonist, therapeutic, stock, takeda, rusfertide, top, market, . One of the sentences in the summary was: Protagonist Therapeutics shares rise 5.6% on licensing deal with takeda. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #protagonist #therapeutic #stock #takeda #rusfertide #top #market.

Read more →

Youtube Subscribe

---